All articles
Are GLP-1 Medications Safe for Thyroid Disorders?
Reading time:
4 min
Weight loss

Get expert guidance and a personalized care plan designed around you.
Medullary Thyroid Cancer and MEN-2
The concern for the development of medullary thyroid cancer when taking GLP-1 medications is still ongoing. An observational study published in 2023 in Diabetes Care that looked to determine whether the use of GLP-1 medications was associated with an increased risk of thyroid cancer found that in 1-3 years of treatment, the risk for thyroid cancer was increased for those taking GLP-1 medications (2). A few things to note about this study is that there was no significant increase in risk for people after three years on these medications. Along with this, the researchers only looked for “thyroid cancer” in general. There are different types of thyroid cancer; the specific type concerning GLP-1 agonist medications is Medullary Thyroid Cancer. This cancer is also very rare, so it is still hard to say there is a genuine increased risk. Nonetheless, your provider may still ask you about a medical history of medullary thyroid cancer or a family history of MEN-2 before starting you on GLP-1 medications. (Related: Is long-term GLP-1 use safe? See what the 10-year data suggests.)
As always, you should discuss your risk for the development of thyroid cancer with your provider before beginning GLP-1 medications and determine if the benefits of taking the medication outway your specific risk level.
Where Can I Learn More?
If you would like to learn more about GLP-1 medications or want to see if you might be eligible for medication-assisted weight loss, check out Mochi Health, where board-certified obesity medicine physicians can offer expertise in this realm!
References:
Hu W, Song R, Cheng R, Liu C, Guo R, Tang W, Zhang J, Zhao Q, Li X, Liu J. Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials. Front Endocrinol (Lausanne). 2022 Jul 11;13:927859. doi: 10.3389/fendo.2022.927859. PMID: 35898463; PMCID: PMC9309474.
Julien Bezin, Amandine Gouverneur, Marine Pénichon, Clément Mathieu, Renaud Garrel, Dominique Hillaire-Buys, Antoine Pariente, Jean-Luc Faillie; GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 1 February 2023; 46 (2): 384–390. https://doi.org/10.2337/dc22-1148
Share this post
Weight loss
More articles















